Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraparotid Bupivacaine and Dexamethasone After Parotidectomy
NCT07812259Phase 1Recruiting
- Sponsor
- CHU Nîmes
- Start
- May 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupivacaine and dexamethasone in Salivary gland fistula and Sialocele, sponsored by CHU Nîmes. Primary endpoints: Local pain post-injection at Day 15, Local intolerance post-injection at Day 15 and 10 more. Started May 2026; status: recruiting.
02
Drugs
bupivacainedexamethasone
03
Conditions
Salivary gland fistulaSialocele
Beyond the preview
Go deeper on NCT07812259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07812259.